Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome-Reference-Cited by-同舟云学术

Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome

Published:2024-07-07 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Guimarães Gabriela Rapozo^ORCID,Maklouf Giovanna Resk,Teixeira Cristiane Esteves^ORCID,de Oliveira Santos Leandro,Tessarollo Nayara Gusmão^ORCID,de Toledo Nayara Evelin,Serain Alessandra Freitas,de Lanna Cristóvão Antunes^ORCID,Pretti Marco Antônio^ORCID,da Cruz Jéssica Gonçalves Vieira,Falchetti Marcelo^ORCID,Dimas Mylla M.^ORCID,Filgueiras Igor Salerno^ORCID,Cabral-Marques Otavio,Ramos Rodrigo Nalio^ORCID,de Macedo Fabiane Carvalho,Rodrigues Fabiana Resende,Bastos Nina Carrossini,da Silva Jesse Lopes^ORCID,Lummertz da Rocha Edroaldo^ORCID,Chaves Cláudia Bessa Pereira^ORCID,de Melo Andreia Cristina,Moraes-Vieira Pedro M. M.^ORCID,Mori Marcelo A.^ORCID,Boroni Mariana^ORCID

Abstract

AbstractTumor-associated myeloid-derived cells (MDCs) significantly impact cancer prognosis and treatment responses due to their remarkable plasticity and tumorigenic behaviors. Here, we integrate single-cell RNA-sequencing data from different cancer types, identifying 29 MDC subpopulations within the tumor microenvironment. Our analysis reveals abnormally expanded MDC subpopulations across various tumors and distinguishes cell states that have often been grouped together, such as TREM2+ and FOLR2+ subpopulations. Using deconvolution approaches, we identify five subpopulations as independent prognostic markers, including states co-expressing TREM2 and PD-1, and FOLR2 and PDL-2. Additionally, TREM2 alone does not reliably predict cancer prognosis, as other TREM2+ macrophages show varied associations with prognosis depending on local cues. Validation in independent cohorts confirms that FOLR2-expressing macrophages correlate with poor clinical outcomes in ovarian and triple-negative breast cancers. This comprehensive MDC atlas offers valuable insights and a foundation for futher analyses, advancing strategies for treating solid cancers.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-49916-4.pdf

Reference123 articles.

1. Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).

2. Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021).

3. Greene, J. T., Brian, B. F. 4th, Senevirathne, S. E. & Freedman, T. S. Regulation of myeloid-cell activation. Curr. Opin. Immunol. 73, 34–42 (2021).

4. Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C. & Allavena, P. Tumor-associated myeloid cells: diversity and therapeutic targeting. Cell. Mol. Immunol. 18, 566–578 (2021).

5. Zhou, X., Liu, X. & Huang, L. Macrophage-mediated tumor cell phagocytosis: opportunity for nanomedicine intervention. Adv. Funct. Mater. 31, 2006220 (2021).